MEMPHIS, Tenn., May 28 /PRNewswire-FirstCall/ -- Justin Leonard was named
this week's CRESTOR(R) (rosuvastatin calcium) Charity Challenge winner for his
first-place standing entering the final round of the FED EX St. Jude Classic.

The CRESTOR(R) Charity Challenge is a season-long competition that recognizes
and rewards the tournament leader entering the final round at 35 PGA TOUR
events. Through the program, now in its second year, AstraZeneca will donate
$3.5 million a year to designated health and PGA TOUR charities. At each of
the selected tournaments, a $100,000 contribution will be made, supporting the
PGA TOUR's "Drive to a Billion" campaign which celebrates the spirit of giving
that has helped the TOUR and its tournaments approach the milestone of $1
billion dollars in charitable giving.

For Leonard's performance, CRESTOR, an AstraZeneca pharmaceutical product,
and the FED EX St. Jude Classic will donate $50,000 to St. Jude Children's
Research Hospital. In addition, $50,000 will be donated to the health care
charity of Leonard's choice. CRESTOR(R) Charity Challenge winners and the
tournament's designated charity will be recognized during the network or cable
telecast of each tournament.

Last year, David Toms was in the lead entering the final round of the FED
EX St. Jude Classic. For his performance, AstraZeneca donated $50,000 to St.
Jude, for a total of $100,000 over the past two years, and Toms donated his
$50,000 to the Christus Schumpert Health System Foundation.

"St. Jude is proud to be the recipient of the CRESTOR Charity Challenge
for the second year in a row," says Richard Shadyac, CEO of ALSAC, the fund-
raising arm of St. Jude. "Our doctors and researchers continue to stay on the
cutting edge of medical advancements through generous donations from such
companies as AstraZeneca. With each breakthrough, St. Jude continues the life-
saving mission of finding cures and saving children."

St. Jude treats patients from all 50 states and more than 80 foreign
countries. No family ever pays for treatments not covered by insurance, and
families without insurance are never asked to pay.

The CRESTOR(R) Charity Challenge is the centerpiece of a multi-year PGA
TOUR partnership with AstraZeneca (NYSE: AZN). Last year, AstraZeneca donated
$2.7 million through the program. Highlights from the 2004 CRESTOR(R) Charity
Challenge included:

* More than 50 charities benefited from the program.
* Vijay Singh topped more than one money list in 2004, leading all
players with five CRESTOR(R) Charity Challenge wins.
* Tom Lehman was the only player to win three straight CRESTOR(R) Charity
Challenges.
* Adam Scott, who won twice, was the only other multiple winner.
* 17 CRESTOR(R) Charity Challenge winners went on to victory in their
respective tournaments.

"After just one year, the CRESTOR(R) Charity Challenge has become a
visible extension of the PGA TOUR's mission of giving back in local
communities throughout America," said Tony Zook, senior vice president,
commercial operations, AstraZeneca U.S. "Through AstraZeneca's support, the
CRESTOR(R) Charity Challenge will play a major role in the PGA TOUR's "Drive
to a Billion" charitable program."

Fans can log on to http://www.crestor.pgatour.com to read about past
CRESTOR(R) Charity Challenge winners and learn more about CRESTOR. CRESTOR is
the presenting sponsor of TOUR Fantasy Golf at http://www.pgatour.com/fantasy
and the PGA TOUR's year-end charity special that will air in December.

About St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for
its pioneering work in finding cures and saving children with cancer and other
catastrophic diseases. Founded by late entertainer Danny Thomas and based in
Memphis, Tenn., St. Jude freely shares its discoveries with scientific and
medical communities around the world. No family ever pays for treatments not
covered by insurance, and families without insurance are never asked to pay.
St Jude is financially supported by ALSAC, its fund-raising organization. For
more information, please visit http://www.stjude.org .

About CRESTOR
CRESTOR (rosuvastatin calcium) is a once-daily prescription medication for
use as an adjunct to diet in the treatment of various lipid disorders
including primary hypercholesterolemia, mixed dyslipidemia and isolated
hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase
inhibitors) class of drug therapy. CRESTOR has not been determined to prevent
heart disease, heart attacks, or strokes. For patients with
hypercholesterolemia and mixed dyslipidemia, the usual recommended starting
dose of CRESTOR is 10 mg. Initiation of therapy with 5 mg once daily should be
considered for patients requiring less aggressive LDL-C reductions or who have
predisposing factors for myopathy. For patients with marked
hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg
starting dose may be considered. AstraZeneca licensed worldwide rights to
CRESTOR from the Japanese pharmaceutical company Shionogi & Co., Ltd.

Important Safety Information
CRESTOR is contraindicated in patients with active liver disease or
unexplained persistent elevations of serum transaminases, in women who are
pregnant or may become pregnant, and in nursing mothers. It is recommended
that liver function tests be performed before and at 12 weeks following both
the initiation of therapy and any elevation of dose, and periodically (e.g.,
semiannually) thereafter.

Rare cases of rhabdomyolysis with acute renal
failure secondary to myoglobinuria have been reported with CRESTOR and with
other drugs in this class. The 40-mg dose of CRESTOR is reserved for those
patients who have not achieved LDL-C goal at 20 mg. CRESTOR should be
prescribed with caution in patients with predisposing factors for myopathy,
such as renal impairment.

Patients should be advised to promptly report
unexplained muscle pain, tenderness, or weakness, particularly if accompanied
by malaise or fever. CRESTOR is generally well-tolerated. Adverse reactions
have usually been mild and transient. The most frequent adverse events thought
to be related to CRESTOR were myalgia (3.3%), constipation (1.4%), asthenia
(1.3%), abdominal pain (1.3%) and nausea (1.3%). A full copy of the
prescribing information for CRESTOR is available at
http://www.astrazeneca-us.com/pi/crestor.pdf or by calling 1-877-420-7249.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of over $21.4
billion and leading positions in sales of gastrointestinal, cardiovascular,
respiratory, oncology and neuroscience products. In the United States,
AstraZeneca is a $9.6 billion healthcare business with more than 12,000
employees. AstraZeneca is listed in the Dow Jones Sustainability Index
(Global) as well as the FTSE4Good Index. For more information about
AstraZeneca, please visit: http://www.astrazeneca-us.com

SOURCE AstraZeneca
Web Site: http://www.astrazeneca-us.com
http://www.crestor.pgatour.com http://www.pgatour.com/fantasy
http://www.stjude.org